Astellas and Twist’s
partnership success
Our collaboration with Astellas helps bring our next-generation checkpoint inhibitor—designed against a
historically challenging target—one step closer to the clinic.
Fill Your Pipeline with Potential
Challenging high-value targets, now druggable with Twist-discovered antibodies
Antibody licensing opportunities from a one-of-a-kind discovery engine
Antibodies continue to expand the boundaries of druggable targets and treatable diseases. Yet bringing a biologic to market, even one that promises to be first- or best-in-class, is filled with pre-clinical and clinical obstacles that can’t be overcome alone.
At Twist Bioscience, we're seeking partnerships with academic, biotech, and biopharma teams to help us translate lead assets from our unique discovery and optimization platform into clinical successes. Through close collaboration, we can break the shackles off of hard-to-drug targets in strategic therapeutic areas, ensuring that no disease is labeled “untreatable” and no patient is left behind.
Our therapeutic focus
.
Why partner with Twist?
.png)
Astellas and Twist’s
What our partners are saying
“
Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients.
Twist Bioscience HQ
681 Gateway Blvd
South San Francisco, CA 94080
